CRTLTVRKC-PLGA-PEG nanoparticles containing imatinib

S2P Peptide-PLGA-PEG nanoparticles containing imatinib/S2P peptide (CRTLTVRKC) conjugated to PLGA-PEG nanoparticles is a sophisticated compound designed for improved delivery of imatinib. This approach aims to enhance the therapeutic efficacy of imatinib, a targeted treatment used primarily for chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs), while minimizing side effects through more effective targeting and controlled release.The nanoparticles can be engineered to also deliver other chemotherapy agents or to administer alongside imatinib to create combination therapies that enhance anti-tumor efficacy.The S2P peptide facilitates targeting specific cancer cells, potentially improving the therapeutic index of imatinib by concentrating the drug where it is most needed.The PLGA matrix allows for controlled release, promoting a prolonged therapeutic effect and minimizing the peaks and troughs associated with traditional dosing regimens.By targeting cancer cells specifically, the risk of side effects associated with systemic drug exposure can be reduced.The PEGylation process enhances the solubility and stability of the nanoparticles, improving bioavailability.

msds of S2P Peptide-PLGA-PEG nanoparticles containing imatinib